Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of the Sinus Headache Screener (SHS).

The Laryngoscope·2026

Same author

Two decades of advancing safe and effective cell-based therapies: a review of the impact, promise, and current limitations of USA regulation 21 CFR Part 1271.

Cytotherapy·2026

Same author

Olfactory cleft biopsy analysis of Alzheimer's disease pathobiology across disease stages.

Nature communications·2026

Same author

Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty.

Cell stem cell·2026

Same author

Injury-specific effect of Schwann cell-derived exosome treatment for peripheral nerve injury.

PloS one·2026

Same author

Differential survival benefit of curative versus non-curative intent treatment in a real-world cohort with early and intermediate-stage hepatocellular carcinoma.

Hepatology communications·2026

Search research articles

Related Experiment Video

Updated: Mar 3, 2026

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs

Published on: December 24, 2015

Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.

Samuel Golpanian^1,2, Darcy L DiFede³, Aisha Khan¹

¹The Interdisciplinary Stem Cell Institute.

The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences

|April 27, 2017

Summary

Allogeneic human mesenchymal stem cells (allo-hMSCs) show promise for treating frailty. This study found allo-hMSC therapy safe and effective, improving physical function and reducing inflammation in older adults.

Keywords:

Cell-based therapy Inflammation Physical function Regenerative medicine

More Related Videos

Preparation and Culture of Myogenic Precursor Cells/Primary Myoblasts from Skeletal Muscle of Adult and Aged Humans

Preparation and Culture of Myogenic Precursor Cells/Primary Myoblasts from Skeletal Muscle of Adult and Aged Humans

Published on: February 16, 2017

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

Related Experiment Videos

Last Updated: Mar 3, 2026

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs

Published on: December 24, 2015

Preparation and Culture of Myogenic Precursor Cells/Primary Myoblasts from Skeletal Muscle of Adult and Aged Humans

Preparation and Culture of Myogenic Precursor Cells/Primary Myoblasts from Skeletal Muscle of Adult and Aged Humans

Published on: February 16, 2017

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

Area of Science:

Gerontology
Regenerative Medicine
Clinical Immunology

Background:

Aging frailty is linked to diminished stem cell repair capacity.
Restoring regenerative function may offer therapeutic benefits for frailty.

Purpose of the Study:

To assess the safety and potential efficacy of intravenous allogeneic human mesenchymal stem cell (allo-hMSC) therapy.
To evaluate allo-hMSC treatment in patients experiencing aging frailty.

Main Methods:

A nonrandomized, dose-escalation Phase 1 study.
Patients received single intravenous infusions of 20, 100, or 200 million allo-hMSCs.
Safety assessed by treatment-emergent serious adverse events; efficacy by functional tests and inflammatory biomarkers.

Main Results:

No serious adverse events or significant immune reactions observed within 6 months.
Significant improvements in 6-minute walk distance (p = .001) and decreased TNF-α levels (p < .0001) were noted.
The 100-million cell dose demonstrated optimal improvements in physical function and quality of life (SF-36).

Conclusions:

Intravenous allo-hMSC therapy is safe and well-tolerated in aging frailty patients.
Observed improvements in functional and immunologic markers support further clinical investigation.
Cell-based therapy warrants continued development for treating frailty.